期刊文献+

Bortezomib depended on PRDM1 and TP53 to exert therapeutic effect in activated B-cell-like diffuse large B-cell lymphoma

原文传递
导出
摘要 PR/SET domain 1(PRDM1)gene is located on chromosome 6q21,encoding the B lymphocyte-induced maturation protein 1(BLIMP1).1 It is reported that loss of PRDM1 function is exacerbated in activated B-cell-like(ABC)-diffuse large B cell lymphoma(DLBCL)and associated with inferior survival.However,it remains unclear what leads to PRDM1 inactivation and the drug resistance mechanism caused by abnormal inactivation of PRDM1.We investigated the contribution of PRDM1 gene as a prognosis and potential therapeutic target for ABC-DLBCL patients and further clarified the possible mechanism of PRDM1 abnormal inactivation.We first proposed that TP53 could regulate PRDM1 by histone ubiquitination modification at the post-transcriptional level.
出处 《Genes & Diseases》 SCIE CSCD 2024年第2期550-553,共4页 基因与疾病(英文)
基金 supported by the National Natural Science Foundation of China(No.81720108002,81700193,82170186) Jiangsu Province's Medical Elite Programme(China)(No.ZDRCA2016022) Project of National Key Clinical Specialty(China),Jiangsu Provincial Special Program of Medical Science(China)(No.BE2017751) National Science and Technology Major F Project(China)(No.2018ZX09734007) Nature Science Foundation for Youths of Jiangsu Province,China(No.BK20220719) China Postdoctoral Science Foundation(No.2021M691336) Jiangsu Post doctoral Science Foundation(China)(No.2021K083A).
关键词 PRDM1 TP53 THERAPEUTIC
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部